Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021

Review Oncology

Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond

Romualdo Barroso-Sousa et al.

Summary: ADCs are a complex class of drugs designed to deliver antineoplastic medicines in a precise and targeted manner, with the aim of treating metastatic breast cancer. Two ADCs have been recently approved by the FDA for breast cancer treatment, with ongoing efforts to develop new agents. Clinical trials could potentially revolutionize the treatment algorithm for early and advanced breast cancer.

BIODRUGS (2021)

Add to Collection

Review Oncology

Unlocking the potential of antibody-drug conjugates for cancer therapy

Joshua Z. Drago et al.

Summary: Nine ADCs are currently approved for cancer treatment, with many more in development. Advances in synthetic biochemistry have led to a new generation of ADCs promising improved tissue specificity and cytotoxicity. Despite impressive activity against treatment-refractory cancers, challenges such as systemic toxicity and acquired resistance remain. This review discusses the design, mechanism of action, and limitations of ADCs, proposing strategies to maximize their therapeutic benefit for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Emerging strategies for treating metastasis

Mark Esposito et al.

Summary: The systemic spread of tumor cells is the major cause of cancer deaths, with few effective therapeutic strategies targeting metastasis. Recent advances in understanding tumor-intrinsic pathways, immune-activating strategies, and emerging areas offer potential for innovative treatments against metastatic cancer. Kang and colleagues review recent progress and challenges in developing therapies for metastatic disease and discuss the clinical implications of ongoing and completed studies.

NATURE CANCER (2021)

Add to Collection

Review Oncology